только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 4 / 9
Страница 1 / 1

Список литературы

  1. Anderson K.E. et al. Recommendations for the diagnosis and treatment of the acute porphyrias // Annals of Internal Medicine. American College of Physicians, 2005. Vol. 142, № 6. P. 439–450.
  2. Kauppinen R. Porphyrias // Lancet. Lancet, 2005. Vol. 365, № 9455. P. 241–252.
  3. Yasuda M., Chen B., Desnick R.J. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes // Molecular Genetics and Metabolism. Academic Press Inc., 2019. Vol. 128, № 3. P. 320–331.
  4. Pischik E., Kauppinen R. An update of clinical management of acute intermittent porphyria // Appl. Clin. Genet. Dove Medical Press Ltd., 2015. Vol. 8. P. 201–214.
  5. Pischik E., Kauppinen R. Neurological manifestations of acute intermittent porphyria // Cell Mol Biol. 2009. Vol. 55, № 1. P. 72–83.
  6. Пустовойт Я.С., Галстян Г.М., Савченко В.Г. Диагностическая роль отдельных синдромов и симптомов в семиотике острых порфирий // Гематология и трансфузиология. 2014. Vol. 3. P. 35–39.
  7. Pischik E., Kazakov V., Kauppinen R. Is screening for urinary porphobilinogen useful among patients with acute polyneuropathy or encephalopathy? // J. Neurol. J Neurol, 2008. Vol. 255, № 7. P. 974–979.
  8. Balwani M. et al. Acute hepatic porphyrias: Recommendations for evaluation and long-term management // Hepatology. John Wiley and Sons Inc., 2017. Vol. 66, № 4. P. 1314–1322.
  9. Stein P. et al. Best practice guidelines on clinical management of acute attacks of porphyria and their complications // Ann. Clin. Biochem. Ann Clin Biochem, 2013. Vol. 50, № 3. P. 217–223.
  10. Пустовойт Я.С. et al. Российский реестр лекарственных препаратов, применяемых у больных с нарушениями порфиринового обмена // Гематология и трансфузилогия. 2015. Vol. 60, № 3. P. 38–43.
  11. Goldberg A. ACUTE INTERMITTENT PORPHYRIA: A Study of 50 Cases // QJM An Int. J. Med. Oxford Academic, 1959. Vol. 28, № 2. P. 183–209.
  12. Stein J.A., Tschudy D.P. Acute intermittent porphyria. A clinical and biochemical study of 46 patients // Med. 1970. Vol. 49, № 1. P. 1–16.
  13. WALDENSTROM J. NEUROLOGICAL SYMPTOMS CAUSED BY SOCALLED ACUTE PORPHYRIA // Acta Psychiatr. Scand. John Wiley & Sons, Ltd, 1939. Vol. 14, № 1–2. P. 375–379.
  14. Ridley A. The neuropathy of acute intermittent porphyria // Q J Med. 1969. Vol. 38, № 151. P. 307–333.
  15. Zheng X. et al. Acute intermittent porphyria presenting with seizures and posterior reversible encephalopathy syndrome: Two case reports and a literature review // Med. (United States). Lippincott Williams and Wilkins, 2018. Vol. 97, № 36.
  16. Kakoullis L. et al. Porphyrias and photosensitivity: pathophysiology for the clinician // Postgraduate Medicine. Taylor and Francis Inc., 2018. Vol. 130, № 8. P. 673–686.
  17. Yrjönen A. et al. A novel 19-bp deletion of exon 15 in the HMBS gene causing acute intermittent porphyria associating with rhabdomyolysis during an acute attack // Clinical Genetics. Clin Genet, 2008. Vol. 74, № 4. P. 396–398.
  18. Balwani M. et al. Acute Intermittent Porphyria in children: A case report and review of the literature // Molecular Genetics and Metabolism. Academic Press Inc., 2016. Vol. 119, № 4. P. 295–299.
  19. Bonkovsky H.L. et al. Acute porphyrias in the USA: Features of 108 subjects from porphyrias consortium // Am. J. Med. Elsevier Inc., 2014. Vol. 127, № 12. P. 1233–1241.
  20. Hift R.J., Meissner P.N. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyrio differ in susceptibility and severity // Medicine (Baltimore). Medicine (Baltimore), 2005. Vol. 84, № 1. P. 48–60.
  21. Woolf J. et al. Best practice guidelines on first-line laboratory testing for porphyria // Annals of Clinical Biochemistry. SAGE Publications Ltd, 2017. Vol. 54, № 2. P. 188–198.
  22. Mustajoki P., Nordman Y. Early administration of heme arginate for acute porphyric attacks // Arch Intern Med. 1993. Vol. 153, № 17. P. 2004–2008.
  23. Watson C.J., Schwartz S. A Simple Test for Urinary Porphobilinogen. // Exp. Biol. Med. SAGE PublicationsSage UK: London, England, 1941. Vol. 47, № 2. P. 393–394.
  24. Kauppinen R., von und zu Frauenberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families // Clin Chem. 2002. Vol. 48, № 11. P. 1891–1900.
  25. Von Und Zu Fraunberg M. et al. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria // Medicine (Baltimore). Medicine (Baltimore), 2005. Vol. 84, № 1. P. 35–47.
  26. Quansah R. et al. Hepatitis C- and HIV-induced porphyria cutanea tarda // Am. J. Case Rep. International Scientific Information, Inc., 2014. Vol. 15. P. 35–40.
  27. ROCCHI E. et al. Hepatitis B virus infection in porphyria cutanea tarda // Liver. Liver, 1986. Vol. 6, № 3. P. 153–157.
  28. Lederhandler M. et al. A case of porphyria cutanea tarda in the setting of hepatitis C infection and tobacco usage // Dermatol. Online J. Dermatology Online Journal, 2019. Vol. 25, № 12. P. 11–12.
  29. Garcia-Silva J., Velasco-Benito J.A., Peña-Penabad C. Primary syphilis with multiple chancres and porphyria cutanea tarda in an HIV-infected patient // Dermatology. 1994.
  30. Tracy J.A., James P., Dyck B. Porphyria and its neurologic manifestations. 2014.
  31. Stölzel U., Doss M.O., Schuppan D. Clinical Guide and Update on Porphyrias // Gastroenterology. 2019.
  32. Oomman A., Gurtoo A. Acute Intermittent Porphyria as a Cause of Acute Respiratory Failure // J. Indian Med. Assoc. 2002.
  33. Watson C.J. et al. Use of hematin in the acute attack of the “inducible” hepatic prophyrias // Adv Intern Med. 1978. Vol. 23. P. 265–286.
  34. Anderson K.E., Collins S. Open-Label Study of Hemin for Acute Porphyria: Clinical Practice Implications // Am. J. Med. Am J Med, 2006. Vol. 119, № 9.
  35. Herrick A.L. et al. CONTROLLED TRIAL OF HAEM ARGINATE IN ACUTE HEPATIC PORPHYRIA // Lancet. Lancet, 1989. Vol. 333, № 8650. P. 1295–1297.
  36. Tschudy D.P. et al. The effect of carbohydrate feeding on the induction of δ-aminolevulinic acid synthetase // Metabolism. Metabolism, 1964. Vol. 13, № 5. P. 396–406.
  37. Handschin C. et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1α // Cell. Cell, 2005. Vol. 122, № 4. P. 505–515.
  38. Anderson K.E. Acute hepatic porphyrias: Current diagnosis & management // Molecular Genetics and Metabolism. 2019.
  39. Яцков К.В. et al. Интенсивная терапия осложнений острой порфирии // Анестезиология и реаниматология. 2015. Vol. 60. P. 37–42.
  40. Kauppinen R., Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases // Med. 1992. Vol. 71, № 1. P. 1–13.
  41. Hift R.J., Thunell S., Brun A. Drugs in porphyria: From observation to a modern algorithm-based system for the prediction of porphyrogenicity // Pharmacology and Therapeutics. Elsevier Inc., 2011. Vol. 132, № 2. P. 158–169.
  42. Пустовойт Я.С. et al. Дифференцированные подходы к интенсивной терапии больных с тяжелым течением острой порфирии // Анестезиология и реаниматология. 2009. Vol. 2. P. 39–45.
  43. Супонева Н., Пирадов М.А., Спирин Н.Н. Синдром Гийена-Барре. Клинические рекомендации. Москва: Горячая линия - Телеком, 2018. P. 32.
  44. Белкин А.А. et al. Реабилитация в интенсивной терапии // Клинические рекомендации. Анестезиология-реаниматология. Под ред. И.Б. Заболотских, Е.М. Шифмана. 2016. P. 858–913.
  45. Innala E. et al. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria // Acta Obstet. Gynecol. Scand. 2010.
  46. Andersson C., Innala E., Bäckström T. Acute intermittent porphyria in women: Clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden // J. Intern. Med. 2003.
  47. De Block C.E.M., De Leeuw I.H., Van Gaal L.F. Premenstrual attacks of acute intermittent porphyria: Hormonal and metabolic aspects - A case report // Eur. J. Endocrinol. 1999.
  48. Yarra P. et al. Benefits of prophylactic heme therapy in severe acute intermittent porphyria // Mol. Genet. Metab. Reports. Elsevier Inc., 2019. Vol. 19.
  49. Naik H. et al. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study // Mol. Genet. Metab. Academic Press Inc., 2016. Vol. 119, № 3. P. 278–283.
  50. Singal A.K. et al. Liver transplantation in the management of porphyria // Hepatology. John Wiley and Sons Inc., 2014. Vol. 60, № 3. P. 1082–1089.
  51. Badminton M.N., Deybach J.-C. Treatment of an acute attack of porphyria during pregnancy // Eur. J. Neurol. 2006. Vol. 13, № 6. P. 668–669.
  52. Marsden J.T., Rees D.C. A retrospective analysis of outcome of pregnancy in patients with acute porphyria // J. Inherit. Metab. Dis. J Inherit Metab Dis, 2010. Vol. 33, № 5. P. 591–596.
  53. Pischik E., Kauppinen R. Can pregnancy stop cyclical attacks of porphyria? // American Journal of Medicine. Elsevier Inc., 2006. Vol. 119, № 1. P. 88–90.
  54. Mirralles A.M.B., Torres-Castro R., Guzman C.O. A Comprehensive Rehabilitation Program and Follow-up Assessment for Acute Intermittent Porphyria // Am. J. Phys. Med. Rehabil. Lippincott Williams and Wilkins, 2017. Vol. 96, № 5. P. e85–e88.
  55. Innala E., Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden // J. Intern. Med. John Wiley & Sons, Ltd, 2011. Vol. 269, № 5. P. 538–545.
  56. Haefeli M., Elfering A. Pain assessment // European Spine Journal. Springer, 2006. Vol. 15, № SUPPL. 1. P. S17.

Для продолжения работы требуется вход / регистрация